Oncotarget: Anaplastic lymphoma kinase rearrangement and non-small cell lung cancer

Oncotarget published "Anaplastic lymphoma kinase rearrangement prevalence in patients with advanced non-small cell lung cancer in the United States: retrospective real world data" which reported that rearrangement prevalence was assessed overall and then stratified by patient characteristics. The overall ALK rearrangement prevalence was 2.6%.

Differences in ALK status also varied by age and race, with young patients having a higher prevalence vs. older patients; Asian patients had a prevalence ... continue reading >>

Oncotarget: Mutational Burden in Lung Cancer Studied in Multisite Cohort

In a trending new research paper published in Oncotarget, researchers conducted a multi-site cohort study of tumor mutational burden among hundreds of patients diagnosed with stage IV non-small cell lung cancer.


BUFFALO, NY-April 25, 2022 – A new research paper, entitled, “Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study,” was published in Oncotarget on January 31, 2022, by researchers from University of Utah, University of... continue reading >>

Oncotarget: A novel isoform of Homeodomain-interacting protein kinase-2

Oncotarget published "A novel isoform of Homeodomain-interacting protein kinase-2 promotes YAP/TEAD transcriptional activity in NSCLC cells" which reported that In this study, the authors show that a new HIPK2 isoform increases TEAD reporter activity in NSCLC cells.

They detected and cloned a novel HIPK2 isoform 3 and found that its forced overexpression promotes TEAD reporter activity in NSCLC cells.

Expressing HIPK2 isoform 3_K228A kinase-dead plasmid failed to increase TEAD reporter... continue reading >>

Oncotarget: Caspase-11 and AIM2 inflammasome involved in COPD and lung adenocarcinoma

Oncotarget published "Caspase-11 and AIM2 inflammasome are involved in smoking-induced COPD and lung adenocarcinoma" which reported that cigarette smoking is the leading risk factor for COPD and lung cancer establishment.

Epidemiologically, COPD patients are 6.35 times more likely to develop lung cancer.

To mimic COPD, the authors exposed mice to nose-only cigarette smoke and used human samples of lung adenocarcinoma patients according to the smoking and COPD status.

Interestingly, higher... continue reading >>

Oncotarget: Distinct differences between molecular profiles of 3D and 2D cultured cells

Oncotarget published "Comparative microsomal proteomics of a model lung cancer cell line NCI-H23 reveals distinct differences between molecular profiles of 3D and 2D cultured cells" which reported that to ascertain phenotypical differences between these two distinct culture conditions, these authors carried out a comparative proteomic analysis of a membrane fraction obtained from 3D- and 2D-cultured NSCLC model cell line NCI-H23.

This analysis revealed a map of 1,166 protein species regulated... continue reading >>

Oncotarget: PD-L1 expression and MET gene amplification in non-small cell lung cancer

Oncotarget published "Correlation between PD-L1 expression and MET gene amplification in patients with advanced non-small cell lung cancer and no other actionable oncogenic driver" which reported that herein, the authors investigated the relation between MET gene amplification and PD-L1 expression in patients with advanced NSCLC and no other actionable oncogenic driver.

PD-L1 expression was not significantly different when analyzed by sex, smoking history, and Eastern Cooperative Oncology... continue reading >>

Oncotarget: mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC

Oncotarget published "High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC" which reported that the aim of this study was therefore to define combination of treatment based on the determination of predictive markers of resistance to the mTORC1 inhibitor RAD001/Everolimus.

When looking at biomarkers of resistance by RT-PCR study, three genes were found to be highly expressed in resistant tumors, i.e., PLK1, CXCR4, and AXL.

The authors have... continue reading >>

Oncotarget: The role of EGFR mutations in predicting recurrence in lung adenocarcinoma

Volume 11, Issue 22 of @Oncotarget reported that while lobectomy can improve mortality in this group, about 30 55% of patients will experience disease recurrence.

The increased investigation into the factors affecting recurrence, particularly tumor molecular genetics such as EGFR mutations, is needed.

These authors conducted a single-center retrospective study of 282 patients with early or locally advanced lung adenocarcinoma, with or without EGFR mutations, who underwent definitive therapy.

... continue reading >>

Oncotarget: Correction of NSE concentration improves diagnostic accuracy in lung cancer

Oncotarget Volume 11, Issue 27 published "Correction of the NSE concentration in hemolyzed serum samples improves its diagnostic accuracy in small-cell lung cancer" by Genet et al. which reported that this study aimed to develop a hemolysis correction equation and evaluate its role in small-cell lung cancer (SCLC) diagnostics.

A hemolysis correction equation was obtained by analyzing the relationship between the measured Neuron-specific enolase (NSE) concentration and the degree of hemolysis.

... continue reading >>

Overall survival in patients with lung adenocarcinoma harboring "niche" mutations: an observational study

The cover for issue 5 of Oncotarget features Figure 2, "Survival curves in the KRAS, EGFR, and niche mutations cohorts," by Aramini, et al.

Mutations were observed in all genes studied, except c-MET, DDR2, MAP2K1, and RET.

The multivariable analysis showed that:

  1. Niche mutations had higher mortality than EGFR mutations
  2. KRAS mutations had higher mortality than EGFR mutations, and
  3. Niche mutations presented similar mortality to KRAS mutations.

Niche mutations exhibited an increased risk of... continue reading >>

Copyright © 2023 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC